Loading...

Natalia Jura, PhD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentCardiovascular Research Inst
Address555 Mission Bay Blvd South
San Francisco CA 94158
Phone415-514-1133
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Structural and Functional Studies of HER Receptor Tyrosine Kinases
    NIH R01GM109176Sep 1, 2014 - Aug 31, 2019
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. 2018 Nov 02. PMID: 30390071.
      View in: PubMed
    2. Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12; 34(5):792-806.e5. PMID: 30449325.
      View in: PubMed
    3. Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT. Activating HER3 mutations in breast cancer. Oncotarget. 2018 Jun 12; 9(45):27773-27788. PMID: 29963236.
      View in: PubMed
    4. Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ. Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Cell Rep. 2018 Mar 06; 22(10):2593-2600. PMID: 29514089.
      View in: PubMed
    5. Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N. Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure. 2018 Feb 06; 26(2):270-281.e4. PMID: 29358026.
      View in: PubMed
    6. Neben CL, Lo M, Jura N, Klein OD. Feedback regulation of RTK signaling in development. Dev Biol. 2017 Oct 26. PMID: 29079424.
      View in: PubMed
    7. Agnew C, Jura N. Switching on BTK-One Domain at a Time. Structure. 2017 Oct 03; 25(10):1469-1470. PMID: 28978404.
      View in: PubMed
    8. van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proc Natl Acad Sci U S A. 2017 04 04; 114(14):E2836-E2845. PMID: 28320942.
      View in: PubMed
    9. Kung JE, Jura N. Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure. 2016 Jan 05; 24(1):7-24. PMID: 26745528; PMCID: PMC4706642 [Available on 01/05/17].
    10. Michael N, Jura N. Src defines a new pool of EGFR substrates. Nat Struct Mol Biol. 2015 Dec; 22(12):945-7. PMID: 26643845.
      View in: PubMed
    11. Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J. Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Mol Cell Biol. 2015 Sep 01; 35(17):3083-102. PMID: 26124280; PMCID: PMC4525312.
    12. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal. 2014 Dec 02; 7(354):ra114. PMID: 25468994; PMCID: PMC4492339.
    13. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA, Ungureanu D, Hammaren H, Silvennoinen O, Varghese LN, Chen K, Tripaydonis A, Jura N, Fukuda K, Qin J, Nimchuk Z, Mudgett MB, Elowe S, Gee CL, Liu L, Daly RJ, Manning G, Babon JJ, Lucet IS. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem J. 2014 Jan 15; 457(2):323-34. PMID: 24107129.
      View in: PubMed
    14. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013 Oct 14; 24(4):438-49. PMID: 24135280; PMCID: PMC3819146.
    15. Littlefield P, Jura N. EGFR lung cancer mutants get specialized. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):15169-70. PMID: 24023066; PMCID: PMC3780895.
    16. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell. 2011 Apr 08; 42(1):9-22. PMID: 21474065; PMCID: PMC3175429.
    17. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A. 2009 Dec 22; 106(51):21608-13. PMID: 20007378.
      View in: PubMed
    18. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009 Jun 26; 137(7):1293-307. PMID: 19563760; PMCID: PMC2814540.
    19. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 2007 Nov 29; 450(7170):741-4. PMID: 18046415; PMCID: PMC3561764.
    20. Jura N, Bar-Sagi D. Mapping cellular routes of Ras: a ubiquitin trail. Cell Cycle. 2006 Dec; 5(23):2744-7. PMID: 17172849.
      View in: PubMed
    21. Archer H, Jura N, Keller J, Jacobson M, Bar-Sagi D. A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen. Gastroenterology. 2006 Dec; 131(6):1844-55. PMID: 17087933.
      View in: PubMed
    22. Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. Differential modification of Ras proteins by ubiquitination. Mol Cell. 2006 Mar 03; 21(5):679-87. PMID: 16507365.
      View in: PubMed
    23. Kilarski WW, Jura N, Gerwins P. An ex vivo model for functional studies of myofibroblasts. Lab Invest. 2005 May; 85(5):643-54. PMID: 15723087.
      View in: PubMed
    24. Mezyk-Kopec R, Bzowska M, Potempa J, Bzowska M, Jura N, Sroka A, Black RA, Bereta J. Inactivation of membrane tumor necrosis factor alpha by gingipains from Porphyromonas gingivalis. Infect Immun. 2005 Mar; 73(3):1506-14. PMID: 15731048; PMCID: PMC1064957.
    25. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005 Jan; 15(1):72-7. PMID: 15686632.
      View in: PubMed
    26. Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-alpha stimulates expression of TNF-alpha converting enzyme in endothelial cells. Eur J Biochem. 2004 Jul; 271(13):2808-20. PMID: 15206946.
      View in: PubMed
    27. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res. 2003 Nov 15; 291(1):70-82. PMID: 14597409.
      View in: PubMed
    28. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr Biol. 2003 Feb 18; 13(4):308-14. PMID: 12593796.
      View in: PubMed